Efavirenz and CYP2C9 Genetic Polymorphisms Reduce CYP2C9 Activity in Healthy Participants
Open Access
- 20 January 2026
- journal article
- Published by Wiley in Clinical and Translational Science
- Vol. 19 (2) , e70476
Abstract
Efavirenz's effects on cytochrome P450 2C9 (CYP2C9) activity have not been formally characterized in vivo. We conducted the first clinical drug–drug interaction (DDI) study to test the effect of chronic efavirenz dosing on CYP2C9 activity, using tolbutamide as a selective probe. Healthy participants received a single oral dose of tolbutamide (250 mg) with a single 600 mg dose of efavirenz (SD) before and after 600 mg daily efavirenz for 17 days (MD). Tolbutamide, efavirenz, and their metabolites were quantified in plasma and urine samples by LC–MS/MS method. Participants were genotyped for CYP2C9*2 and *3 and for CYP2B6*4, *9, and *18. Pharmacokinetic data were valid for 71 and 59 participants for SD‐ and MD groups, respectively. MD efavirenz caused more than 50% increase in median tolbutamide AUC 0‐∞ and C 24 in all subjects, and 1.42–1.46‐fold increase in the paired analysis ( p < 0.0001); tolbutamide/metabolite ratios were also increased ( p < 0.001), while tolbutamide's CL/F/kg, metabolite formation clearance, and metabolite C max were significantly reduced. CYP2C9 genetic variants were associated with reduced tolbutamide elimination compared to *1/*1 and *1/*2 (slowest, *3/*3; and intermediate, *1/*3, *2/*2, and *2/*3). The lowest percent change occurred in *2/*2 and * 3/*3 genotypes, though small sample sizes limited reliable assessment of genotype‐specific DDI effects. In conclusion, chronic efavirenz use inhibits CYP2C9 activity in vivo. This inhibition may increase the risk of adverse effects from narrow‐therapeutic‐index CYP2C9 substrates (e.g., warfarin, phenytoin, and sulfonylureas). Therefore, therapeutic drug monitoring and dose adjustments are warranted when efavirenz is co‐administered with these medications.Keywords
This publication has 47 references indexed in Scilit:
- REGULATION OF CYP2B6 IN PRIMARY HUMAN HEPATOCYTES BY PROTOTYPICAL INDUCERSDrug Metabolism and Disposition, 2004
- Induction of Human CYP2C9 by Rifampicin, Hyperforin, and Phenobarbital Is Mediated by the Pregnane X ReceptorThe Journal of Pharmacology and Experimental Therapeutics, 2004
- Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male volunteersClinical Therapeutics, 2003
- The Cytochrome P450 2B6 (CYP2B6) Is the Main Catalyst of Efavirenz Primary and Secondary Metabolism: Implication for HIV/AIDS Therapy and Utility of Efavirenz as a Substrate Marker of CYP2B6 Catalytic ActivityThe Journal of Pharmacology and Experimental Therapeutics, 2003
- Pxr, car and drug metabolismNature Reviews Drug Discovery, 2002
- Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and the insulin and glucose response in healthy volunteers.2002
- Comparisons between in-vitro and in-vivo metabolism of (S)-warfarin: catalytic activities of cDNA-expressed CYP2C9, its Leu359 variant and their mixture versus unbound clearance in patients with the corresponding CYP2C9 genotypesPharmacogenetics, 1998
- Cytochrome P4502C9: an enzyme of major importance in human drug metabolismBritish Journal of Clinical Pharmacology, 1998
- Drug Interactions with FluconazoleClinical Infectious Diseases, 1990
- Cotrimoxazole as an inhibitor of oxidative drug metabolism: effects of trimethoprim and sulphamethoxazole separately and combined on tolbutamide disposition.British Journal of Clinical Pharmacology, 1985